Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623816 · ClinicalTrials.gov registry record · Phase 4
Symptom Control Satisfaction With Proton Pump Inhibitor Regimen
A Phase 4 study, sponsored by MetroHealth Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT02623816 is a Phase 4 study that has completed, run by MetroHealth Medical Center. The registered enrollment target is 64 participants.
The verdict
NCT02623816, a Phase 4 study, has completed, sponsored by MetroHealth Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The overall aim of this study is to assess if patients with persistent gastroesophageal reflux disease (GERD) symptoms receiving sub-optimal omeprazole dosing experience improvement in GERD symptoms when prescribed an optimal dosing regimen. The optimal dosing regimen is defined as taking omeprazole 30 minutes prior to the first meal of the day.
Interventions
- DRUG Optimal Dosing of Omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02623816
The ClinicalTrials.gov registry entry for NCT02623816 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MetroHealth Medical Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optimal Dosing of Omeprazole is the first listed.
NCT02623816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02623816 about?
NCT02623816 is a clinical study titled "Symptom Control Satisfaction With Proton Pump Inhibitor Regimen". The overall aim of this study is to assess if patients with persistent gastroesophageal reflux disease (GERD) symptoms receiving sub-optimal omeprazole dosing experience improvement in GERD symptoms when prescribed an optimal dosing regimen. The optimal dosing regimen is defined as taking omeprazole...
What is the current status of trial NCT02623816?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2014-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02623816?
The interventions under investigation include: Optimal Dosing of Omeprazole (DRUG).
Who is sponsoring clinical trial NCT02623816?
This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.